Form 8-K LEXICON PHARMACEUTICALS, For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Lexicon Pharma (LXRX) Tops Q3 EPS by 2c
November 6, 2015 9:15 AM ESTLexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.34), $0.02 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $566 thousand versus the consensus estimate of $370 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... MoreSanofi (SNY), Lexicon Pharma (LXRX) Enter Sotagliflozin Commercialization, Development Agreement
November 6, 2015 6:26 AM ESTSanofi (NYSE: SNY) and Lexicon Pharma (Nasdaq: LXRX) announced that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
"This agreement with Lexicon reinforces our commitment to helping people living with diabetes," said Pascale Witz, Executive Vice President, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the company's new organizational structure. "Adding... More
